PCN116 Participation In Cervical Cancer Screening And Knowledge On Human Papillomavirus Among Women In Vác, Hungary  by Vajda, R. et al.
 VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 1 – A 3 0 7  A209
OBJECTIVES: Decisions on palliative chemotherapy (CT) for advanced gastric cancer 
require trade-offs between potential benefits and risks for patients. Healthcare 
providers and payers agreed that patient preferences should be considered. We 
conducted a CBC study in patients with mGC or mGEJ-Ca from Germany to evaluate 
their preferences when trading-off between treatment tolerability, quality of life 
and survival benefit. METHODS: German oncologists were contacted to identify 
patients with mGC or mGEJ-Ca who had completed ≥ 2 cycles of palliative CT (ongo-
ing or completed). The primary objective was the quantitative evaluation of patient 
preferences for palliative CT in this population by CBC analysis. The CBC matrix, 
developed based on 6 in-depth qualitative interviews, spanned the 3 attributes 
ability to self-care as a key component for quality of life, treatment toxicity and 
survival benefit (3-4 factor levels each, 15 iterations). A minimum of 50 partici-
pants was needed. Eligible consenting patients completed the 45min standardized 
CBC-survey, choosing systematically among profiles. CBC models were estimated 
by mixed-logit regression (MLR) and hierarchical Bayes analysis (HB). Estimates of 
importance for each attribute and factor-level were calculated. RESULTS: Overall, 
55 patients participated in the survey (78% male, median age 63yrs, 82% currently 
receiving CT). Patients considered low treatment toxicity as most important (45% 
relative importance, MLR analysis), followed by ability to self-care (32%) and an 
additional survival benefit of up to 3 months (3 months 23%, 2 months 18%, 1 month 
11%). The MLR analysis showed high validity (certainty 37.9%, chi square p< 0.01, root 
likelihood 0.505). The HB analysis yielded similar results. CONCLUSIONS: Patient 
preferences related to palliative CT of gastric cancer can appropriately be assessed 
by CBC analysis. Though patients’ varied experiences with chemotherapy may have 
impacted specific responses, across the population of patients with mGC or mGEJ-Ca 
improved treatment tolerability and quality of life were ranked highest.
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OBJECTIVES: The main objective of our study was to assess the population’s 
participation in cervical smear testing and knowledge on HPV, also learn about 
women’s attitudes about the vaccine. METHODS: The quantitative cross-sectional 
questionnaire survey was performed among women in a Hungarian town, Vác in 
2013. 150 questionnaires were distributed, of which 120 proved to be evaluable. The 
study was performed with χ 2-test and t-test as a statistical method besides 95% 
probability (p< 0.05). We used SPSS version 20.0 program. RESULTS: 85.5% of the 
respondent women had cervical smear tests. 89.2% of respondent women reported 
an annual visit for screening. Their average age was 22.01±.5.8SD years when they 
first attended screening. Women participated in screening were significantly (t= 4.89, 
p< 0,001) older (36.56), than those who never took part in (26.62). Five questions in 
the survey concerned knowledge on HPV. On the basis of these questions only 27.9% 
of the women had adequate knowledge. The majority of women (80.8%) knew the 
meaning of the acronym HPV, at the same time only 29.2% of them knew that the 
infection affected “both men and women”. Concerning prevention only women 
living in marriage or cohabitation (χ 2= 20.00, p= 0.001) were significantly better 
informed on the issue than single mothers. 85% of the respondent women heard 
about the vaccination against HPV. Only 10 women of the respondents had HPV 
vaccination, and significantly more women over 34 years of age would require vac-
cination for themselves (χ 2= 9.010, p= 0.011) and their daughters (χ 2= 7.415, p= 0.006) 
than their younger counterparts. CONCLUSIONS: Women reported an extremely 
high participation rate in cervical cancer screening, however the overall awareness 
of human papillomavirus in the respondents is superficial (27.9%), therefore, their 
willingness for vaccination is not adequate. In the future, a wide range of informa-
tion should be provided for them to enhance their awareness.
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OBJECTIVES: Patient reported outcomes (PROs) have gained a prominent place in 
clinical research. Previous estimates suggest that PRO measures are used in 14% of 
clinical trials. Online registries, such as ClinicalTrials.gov, may be useful for updat-
ing the extent of PRO use. The objectives of this study were to: (1) estimate the 
proportion of clinical trials that include at least one PRO measure, and (2) examine 
associations between trial characteristics and the use of PRO measures. Particular 
emphasis was given to evaluation of use in oncology studies. METHODS: A local 
copy of the ClinicalTrials.gov database was made containing all data from November 
2007 to December 2013. Content was searched for use of PRO measures. Multivariate 
logistic regression was used to investigate possible associations between trial-level 
characteristics and use of PRO measures. RESULTS: Of 96,736 registered trials, 
25,880 (27%) were identified as using one or more PRO measure. Among oncology 
trials, 29% (3,947/13,584) were identified as using a PRO measure, compared to 26% 
(21,933/83,152) of non-oncology trials. Trials using PRO measures were more likely 
to be sponsored by university/research organizations (29%) or the US government 
(33%); Phase III (35%); randomized (32%); and evaluating devices (30%), procedures 
(32%) or behaviors (50%), compared to drugs (24%). They were less likely to be reg-
ulated by the FDA (23%). CONCLUSIONS: Between 2007 and 2013, there was an 
increase in the number of trials using a PRO measure, particularly in oncology trials. 
The increased use may be attributed, in part, to the changing landscape of patient-
centered care and stakeholder engagement in general. With recent initiatives such 
as the Patient-Focused Drug Development and the NIH-sponsored Patient-Reported 
Outcomes Measurement Information System, the use of PRO measures in clinical 
research will likely increase further.
through the inclusion of studies identified in references lists. Of these 27 stud-
ies, only one provided a statistical regression model describing a relationship 
between FACT-G and EQ-5D in individuals with malignant melanoma. While the 
analyses and data used were described appropriately and satisfied the majority of 
recommendations in the published checklist, the preference-based utility weights 
used in this study were not obtained from the UK population. CONCLUSIONS: 
This study confirms there is very little evidence which could be used to generate 
preference-based utility scores from FACT data. Although one relationship was 
identified which could be used to estimate proxy preference-based utility scores, 
it is not ideal for the UK.
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OBJECTIVES: As part of the Lilly Oncology Patient Access to Cancer care Excellence 
(PACE) initiative, the 2014 PACE Cancer Perceptions Index survey was conducted 
to identify general public perceptions of cancer and its treatment in South 
Korea. METHODS: The general public consisted of a nationally representative 
sample of 500 respondents aged ≥ 18 years who participated in telephone inter-
views initiated by random digit dialing from March 25 to April 22, 2014. Responses 
were evaluated by analysis of frequencies of responses and mean scores. RESULTS: 
Less than half (39%) of the general public expressed satisfaction with progress in 
cancer treatment, and most (82%) believe it takes too long for new cancer medi-
cines to reach patients. Most (68%) of the general public believe clinical trials offer 
patients a chance to receive better treatments than those currently available, and 
the majority (82%) would be willing to participate in a clinical trial if they might 
receive a life-extending treatment. Most of the general public strongly agreed on 
the need for coordination of efforts across national borders (96%), and greater col-
laboration among government, academic institutions, non-profit organizations, 
and pharmaceutical companies (96%), in the development of new cancer medi-
cines. CONCLUSIONS: The general public in South Korea is ambivalent toward 
overall progress in the fight against cancer, and impatient with the pace of pro-
gress. Despite some differences in perceptions in South Korea compared to those 
previously published for PACE surveys in the United States, France, Germany, Italy, 
Japan, and the United Kingdom, the general public in South Korea is consistent 
with the general public in the other six countries in identifying cancer as a health 
priority, and wanting greater investment in addressing the disease as well as faster 
availability of new medicines.
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OBJECTIVES: Studies designed to assess the psychosocial factors affecting 
patients with mCRPC are sparse. Understanding this area may help patients 
and their caregivers communicate and make informed treatment decisions 
with their physicians. We used qualitative research methods to explore patient, 
caregiver, and physician experiences with oral oncolytic therapy. METHODS: 
Our ecological approach postulates that patient, caregiver, and physician treat-
ment decisions and experiences around mCRPC can result from multiple factors 
impacting individuals via social, organizational, community, governmental pol-
icy, and economic influences. Interview guides were developed and tested using 
core concepts of the ecological health model, and conducted with three relevant 
stakeholder groups: 30 patients with mCRPC, 26 caregivers, and an independent 
sample of 30 physicians (oncologists and urologists) who actively treat mCRPC. 
Patients and physicians were identified from a national claims database and car-
egivers were nominated by consented patients. Demographic information was 
collected on patients. Interviews were approved by an Independent Institutional 
Review Board. Interview responses were coded into QSR-NVIVO-10 software and 
analyzed using grounded theory. RESULTS: The majority of patients were age ≥ 70 
years and Caucasian. Patients were taking either abiraterone acetate (32%) or enza-
lutamide (48%). Spouses were the predominant caregiver (89%). Physician specialty 
was stratified into oncologists (77%) and urologists (23%). Six major themes were 
identified: relationship with physicians; effects of disruptions to patients’ physical 
and social activities; communication with physicians; access to the medications; 
role of attitudes in coping with CRPC; and supports and communication. All stake-
holders cited financial factors impacting access to treatment. CONCLUSIONS: There 
were different perspectives on the primary concerns around mCRPC, with patients 
citing loss of social functioning, caregivers fearing that patients would die, and 
physician citing pain. By improving understanding of these experiences, opportuni-
ties exist to improve treatment-related decisions for patients with mCRPC. These 
findings can also inform future quantitative population-based studies.
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